Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.5c01617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Ruiyue Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong510120, China. Hauptthemen laut MEDLINE: Diphosphonates, Bone Neoplasms, Gallium Radioisotopes, Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Bone metastases and associated skeletal-related events (SREs) severely compromise the survival and quality of life of patients with advanced cancer. Although bisphosphonates enable efficient bone targeting, their radiolabeled analogues exhibit limited uptake in osteolytic lesions due to the low hydroxyapatite content. Fibroblast activation protein, highly expressed in cancer-associated fibroblasts within the tumor microenvironment, provides tumor specificity and may enhance tracer accumulation in osteolytic bone metastases. To overcome this limitation, we developed two heterodimeric [68Ga]Ga/[177Lu]Lu-DOTA-FAPI-bisphosphonate radioligands ([68Ga]Ga/[177Lu]Lu-DFP-1/2) by integrating a FAP-targeting moiety with a bisphosphonate backbone. Both compounds were synthesized with high radiochemical purity (>95%) and excellent in vitro stability. In A549-FAP xenograft models, dynamic PET/CT imaging revealed comparable tumor uptake of [68Ga]Ga-DFP-1/2 and [68Ga]Ga-FAPI-04 up to 2 h postinjection, with [68Ga]Ga-DFP-2 demonstrating faster clearance from nontarget organs. In tibial A549-FAP osteogenic models, [68Ga]Ga-DFP-2 showed significantly higher uptake (4.88 ± 1.01% ID/mL) than mono-FAP or monobisphosphonate tracers (p < 0.05). In osteolytic A549 models, [68Ga]Ga-DFP-2 uptake (3.16 ± 0.82% ID/mL) also exceeded that of monobisphosphonate tracers (p < 0.01). Biodistribution studies confirmed prolonged [177Lu]Lu-DFP-2 retention (26.94 ± 4.40% ID/g at 168 h). Collectively, these findings demonstrate that [68Ga]Ga/[177Lu]Lu-DFP-2 possesses favorable dual bone- and tumor-targeting characteristics and holds strong translational promise as a novel theranostic agent for the imaging and treatment of lung cancer bone metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong510120, China.
- College of Chemistry, Beijing Normal University, Beijing100875, China.
- Department of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University…
ORCID-Profile: Shaoyu Liu, Lin Zhu, Xinlu Wang
Förderung
- National Natural Science Foundation of China
- Guangzhou Basic and Applied Basic Research Foundation
Zitieren
APA
Zhao, R., Deng, Y., Jin, W., Xu, M., Liang, W., Liu, S., Zhong, J., Lv, J., He, J., Zhu, L., & Wang, X. (2026). Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01617
Vancouver
Zhao R, Deng Y, Jin W, Xu M, Liang W, Liu S, et al. Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01617
BibTeX
@article{Zhao2026,
author = {Zhao, Ruiyue and Deng, Yuling and Jin, Wenbin and Xu, Mingheng and Liang, Wanmei and Liu, Shaoyu and Zhong, Jiawei and Lv, Jie and He, Jianxing and Zhu, Lin and Wang, Xinlu},
title = {Development and Preclinical Evaluation of Dual-Target 68Ga/177Lu-Labeled FAP-Bisphosphonate Radioligands with Enhanced Osteoma Retention},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.5c01617}
}
EUVIMED